Multimodal neuroprotective therapy with induced hypothermia after ischemic stroke.
Neuroprotective therapies have so far failed to provide improved neurological function and outcome after stroke. A recent focus on multimodal therapies, including the combination of neuroprotective medications with hypothermia, opens a promising new treatment strategy. Advances in hypothermia administration make it one of the most promising neuroprotective therapies available and an ideal candidate for combination with other neuroprotective approaches.
Hemmen
Thomas M
TM
Department of Neuroscience, University of California, San Diego, 200 West Arbor Drive, MC 8466, OPC 3rd Floor, Suite 3, San Diego, CA 92103-8466, USA. themmen@ucsd.edu
Lyden
Patrick D
PD
D000818:Animals; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D007036:Hypothermia, Induced; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D020521:Stroke / Q000628:therapy*; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D018696:Neuroprotective Agents; D010959:Tissue Plasminogen Activator